Vaccines for seasonal and pandemic influenza

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 2, 2006, Pages

  Nichol, Kristin L ^a   Treanor, John J ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; DUCK SINGAPORE VACCINE; H5 ANTIGEN; INACTIVATED VACCINE; INFLUENZA H5N1 VACCINE; INFLUENZA H5N3 VACCINE; INFLUENZA H9N2 VACCINE; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RECOMBINANT H1 RHA VACCINE; RECOMBINANT H3 RHA VACCINE; RECOMBINANT H5 RHA VACCINE; SUBVIRION RGA VETNAM 1203 04 VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

CLINICAL TRIAL; COLD ACCLIMATIZATION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; EPIDEMIC; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INJECTION SITE REACTION; LICENSING; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHINORRHEA; SEASONAL VARIATION; UNITED STATES; VIRION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ALUM COMPOUNDS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HEALTH PRIORITIES; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; POLYSORBATES; RISK FACTORS; SEASONS; SQUALENE; UNITED STATES; VACCINATION; VACCINES, SYNTHETIC;

EID: 33750286032     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507544     Document Type: Review

References (46)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncitial virus in the United States. JAMA 2003; 289:179-86.
2. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Washington, DC: National Center for Health Statistics. Vital Health Stat 10 1999:1-203.
3. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
4. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999; 5:659-71.
5. Centers for Disease Control and Prevention. Preventing the flu. Available at: http://www.cdc.gov/flu/protect/stopgerms.htm. Accessed 8 February 2006.
6. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2005; 54 (RR08):1-40.
7. Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother 2000; 54:210-8.
8. Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005; 365:773-80.
9. Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005; 23:2851-61.
10. MedImmune. Peliminary data from CAIV-T pivotal phase 3 trial demonstrate clinical efficacy over flu shot in head-to-head influenza study. Press release, December 12, 2005. Available at: http://phx.corporate -ir.net/phoenix.zhtml?c= 83037&p=irol-newsArticle&ID=794727 &highlight. Accessed 12 April 2006.
11. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). Cochrane Database Syst Rev 2004; 3:CD001269.
12. Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic or molecular detection of influenza. Arch Intern Med 2001; 161:2116-22.
13. Hak E, Buskens E, van Essens GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions. Arch Intern Med 2005; 165:274-80.
14. Vu T, Parish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20:1831-6.
15. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:1165-74.
16. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123:518-27.
17. Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis 2002; 13:72-7.
18. Health Protection Agency. Influenza A outbreak in a community hospital in south east Wales where few healthcare workers had received immunization. February 2005. CDR Weekly 2005; 15(8). Available at: http://www.hpa.org.uk/cdr/ archives/2005/cdr0805.pdf. Accessed 8 February 2006.
19. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000; 284:1677-82.
20. Monto AS, Davenport FM, Napier JA, Francis T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970; 122:16-25.
21. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005; 23:1540-8.
22. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344:889-96.
23. Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 2006; 24:1047-62.
24. Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000; 355:93-7.
25. Burls A, Jordan R, Barton P, et al. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006; 24:4212-21.
26. Nichol KL, Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Research 2004; 103:3-8.
27. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21:1769-75.
28. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination in children. Vaccine 2005; 23:1004-14.
29. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2207-17.
30. Rothberg MB. Rose DN, Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118:68-77.
31. Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006; 24:1562-8.
32. Centers for Disease Control and Prevention. Estimated influenza vaccination coverage among adults and children-United States, September 1, 2004-January 31, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:304-7.
33. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis 2006; 12:73-7.
34. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF-59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
35. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
36. Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995; 171:1595-8.
37. Treanor JJ, Betts RF, Smith GE, et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 1996; 173:1467-70.
38. Lakey DL, Treanor JJ, Betts RF, et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996; 174:838-41.
39. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
40. Stephenson I, Nicholson KG, Glück R, et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959-66.
41. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93.
42. Hehme N, Engelmann H, Künzel W, Neumeier E, Sänger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002; 191:203-8.
43. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminium-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71.
44. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
45. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94.
46. Patel SM, Atmar RL, El Sahly H, Couch RB, Keitel WA. A randomized, open-label, phase I clinical trial comparing the safety, reactogenicity, and immunogenicity of immunization with inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route among healthy adults (abstract VI-4). In: Program and abstracts of the VIII International Symposium on Respiratory Viral Infections (Kohala, HI). New York: McCrae Group, 2006.